CN107106650A - 用于预防或治疗表征为异常的成纤维细胞增殖和细胞外基质沉积的疾病、状况或过程的组合物和方法 - Google Patents

用于预防或治疗表征为异常的成纤维细胞增殖和细胞外基质沉积的疾病、状况或过程的组合物和方法 Download PDF

Info

Publication number
CN107106650A
CN107106650A CN201580062363.0A CN201580062363A CN107106650A CN 107106650 A CN107106650 A CN 107106650A CN 201580062363 A CN201580062363 A CN 201580062363A CN 107106650 A CN107106650 A CN 107106650A
Authority
CN
China
Prior art keywords
seq
polypeptide
amino acid
acid sequence
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580062363.0A
Other languages
English (en)
Chinese (zh)
Inventor
C.兰德
C.布罗菲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Moerae Matrix Inc
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of CN107106650A publication Critical patent/CN107106650A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN201580062363.0A 2014-11-17 2015-11-17 用于预防或治疗表征为异常的成纤维细胞增殖和细胞外基质沉积的疾病、状况或过程的组合物和方法 Pending CN107106650A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080784P 2014-11-17 2014-11-17
US62/080784 2014-11-17
PCT/US2015/061118 WO2016081475A1 (en) 2014-11-17 2015-11-17 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Publications (1)

Publication Number Publication Date
CN107106650A true CN107106650A (zh) 2017-08-29

Family

ID=55960752

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580062363.0A Pending CN107106650A (zh) 2014-11-17 2015-11-17 用于预防或治疗表征为异常的成纤维细胞增殖和细胞外基质沉积的疾病、状况或过程的组合物和方法

Country Status (13)

Country Link
US (1) US10500249B2 (enExample)
EP (1) EP3220943A4 (enExample)
JP (1) JP2018501201A (enExample)
KR (1) KR20170083063A (enExample)
CN (1) CN107106650A (enExample)
AU (1) AU2015350151A1 (enExample)
BR (1) BR112017010238A2 (enExample)
CA (1) CA2967621A1 (enExample)
MX (1) MX2017006372A (enExample)
RU (1) RU2017121090A (enExample)
SG (1) SG11201703939XA (enExample)
WO (1) WO2016081475A1 (enExample)
ZA (1) ZA201703305B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108795935A (zh) * 2018-05-23 2018-11-13 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 日本血吸虫SjELAV-like 1基因的siRNA及其应用
CN110575540A (zh) * 2018-06-07 2019-12-17 中山大学附属第六医院 Pdgf抑制剂用于制备治疗肠道炎症疾病的药物方面的用途
CN111050786A (zh) * 2017-09-08 2020-04-21 百时美施贵宝公司 用于治疗非酒精性脂肪性肝炎(nash)的方法的修饰的成纤维细胞生长因子21(fgf-21)
CN113134116A (zh) * 2020-01-20 2021-07-20 山东威高药业股份有限公司 内镜微创手术用的填充组合物及填充制剂
CN113730551A (zh) * 2021-09-02 2021-12-03 徐州医科大学 Mmi-0100短肽化合物在制备胆汁淤积性肝病治疗药物中的应用
CN118388635A (zh) * 2024-06-24 2024-07-26 山东美瑞生物技术有限公司 一种提高皮肤修复功能的重组人源化胶原蛋白的制备方法
CN118571492A (zh) * 2024-08-02 2024-08-30 天津市胸科医院 基于组织边界影响的主动脉夹层患者并发症风险预测模型

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019070908A1 (en) 2017-10-03 2019-04-11 Cedars-Sinai Medical Center METHODS OF TARGETING THE PD1 PATHWAY OF THE IMMUNE CONTROL POINT FOR THE TREATMENT OF PULMONARY FIBROSIS
CN113952821A (zh) * 2021-07-22 2022-01-21 上海安居乐环保科技股份有限公司 一种罐区装卸区废气综合治理方法及系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090196927A1 (en) * 2007-01-10 2009-08-06 Alyssa Panitch Polypeptide Inhibitors of HSP27 Kinase and Uses Therefor
CN102316731A (zh) * 2008-12-10 2012-01-11 普渡研究基金会 基于细胞渗透性肽的激酶抑制剂
WO2012142320A2 (en) * 2011-04-12 2012-10-18 Moerae Matrix Inc Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
LU85034A1 (fr) 1982-10-08 1985-06-19 Glaxo Group Ltd Dispositifs en vue d'administrer des medicaments a des patients
GB2178965B (en) 1985-07-30 1988-08-03 Glaxo Group Ltd Devices for administering medicaments to patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DK0733059T3 (da) 1993-12-09 2000-10-16 Univ Jefferson Forbindelser og fremgangsmåder til site-rettede mutationer i eukaryote celler
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
PT1165050E (pt) 1999-04-05 2006-06-30 Mannkind Corp Processos para formacao de po fino
EP1808438B1 (en) 1999-06-29 2014-10-01 MannKind Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
CA2575684A1 (en) 2004-08-23 2006-03-02 Mannkind Corporation Pulmonary delivery of inhibitors of phosphodiesterase type 5
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
WO2007033372A2 (en) 2005-09-14 2007-03-22 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
DK1986679T3 (da) 2006-02-22 2017-11-20 Mannkind Corp Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
US8741849B2 (en) 2007-01-10 2014-06-03 Purdue Research Foundation Kinase inhibitors and uses thereof
NL1033850C2 (nl) 2007-05-15 2008-11-18 3Force B V Brandersysteem met voorgemengde branders en vlam-overdrachtsmiddelen.
CN102256613B (zh) * 2008-10-20 2014-09-10 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽
EP2575855A4 (en) 2010-05-24 2014-03-12 Moerae Matrix Inc METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE
US9452218B2 (en) 2012-03-09 2016-09-27 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
US9750718B2 (en) * 2012-12-12 2017-09-05 The Charlotte-Mecklenburg Hospital Authority Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090196927A1 (en) * 2007-01-10 2009-08-06 Alyssa Panitch Polypeptide Inhibitors of HSP27 Kinase and Uses Therefor
CN102316731A (zh) * 2008-12-10 2012-01-11 普渡研究基金会 基于细胞渗透性肽的激酶抑制剂
WO2012142320A2 (en) * 2011-04-12 2012-10-18 Moerae Matrix Inc Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BATALLER R等: "Liver fibrosis", 《THE JOURNAL OF CLINICAL INVESTIGATION》 *
夏海珊等: "肝纤维化的发病机制和药物治疗现况", 《中国医药导报》 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111050786A (zh) * 2017-09-08 2020-04-21 百时美施贵宝公司 用于治疗非酒精性脂肪性肝炎(nash)的方法的修饰的成纤维细胞生长因子21(fgf-21)
CN108795935A (zh) * 2018-05-23 2018-11-13 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 日本血吸虫SjELAV-like 1基因的siRNA及其应用
CN108795935B (zh) * 2018-05-23 2022-06-21 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 日本血吸虫SjELAV-like 1基因的siRNA及其应用
CN110575540A (zh) * 2018-06-07 2019-12-17 中山大学附属第六医院 Pdgf抑制剂用于制备治疗肠道炎症疾病的药物方面的用途
CN110575540B (zh) * 2018-06-07 2021-11-02 中山大学附属第六医院 Pdgf抑制剂用于制备治疗肠道炎症疾病的药物方面的用途
CN113134116A (zh) * 2020-01-20 2021-07-20 山东威高药业股份有限公司 内镜微创手术用的填充组合物及填充制剂
CN113134116B (zh) * 2020-01-20 2022-09-06 山东威高宏瑞医学科技有限公司 内镜微创手术用的填充组合物及填充制剂
CN113730551A (zh) * 2021-09-02 2021-12-03 徐州医科大学 Mmi-0100短肽化合物在制备胆汁淤积性肝病治疗药物中的应用
CN113730551B (zh) * 2021-09-02 2022-11-25 徐州医科大学 Mmi-0100短肽化合物在制备胆汁淤积性肝病治疗药物中的应用
CN118388635A (zh) * 2024-06-24 2024-07-26 山东美瑞生物技术有限公司 一种提高皮肤修复功能的重组人源化胶原蛋白的制备方法
CN118571492A (zh) * 2024-08-02 2024-08-30 天津市胸科医院 基于组织边界影响的主动脉夹层患者并发症风险预测模型
CN118571492B (zh) * 2024-08-02 2024-10-18 天津市胸科医院 基于组织边界影响的主动脉夹层患者并发症风险预测模型

Also Published As

Publication number Publication date
KR20170083063A (ko) 2017-07-17
SG11201703939XA (en) 2017-06-29
US20160136234A1 (en) 2016-05-19
AU2015350151A1 (en) 2017-06-01
EP3220943A1 (en) 2017-09-27
WO2016081475A1 (en) 2016-05-26
EP3220943A4 (en) 2018-08-01
CA2967621A1 (en) 2016-05-26
RU2017121090A3 (enExample) 2019-06-10
US10500249B2 (en) 2019-12-10
ZA201703305B (en) 2020-05-27
MX2017006372A (es) 2017-08-21
JP2018501201A (ja) 2018-01-18
RU2017121090A (ru) 2018-12-20
BR112017010238A2 (pt) 2018-02-06

Similar Documents

Publication Publication Date Title
JP6031510B2 (ja) 異常な線維芽細胞増殖及び細胞外マトリックスの沈着を特徴とする疾患、症状又はプロセスを予防又は治療する組成物及び方法
US10500249B2 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
JP6655547B2 (ja) 慢性肺移植片機能不全（ｃｌａｄ）および特発性肺線維症（ｉｐｆ）を予防または処置するための組成物および方法
US9890200B2 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
NZ616672B2 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
HK1194983B (en) Compositions and methods for preventing or treating pulmonary fibrosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170829